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tution. Cost (not charges) of the index hospitalization
included direct and indirect costs and was normalized to
2010 values. Data are mean /- S.D.
Results: 306 patients underwent either CEA (n174)
or CAS (n132). Patients undergoing CEA trended to-
wards a higher prevalence of being symptomatic (44.8
%)compared to CAS(34.0%,P 0.09). Age was not signif-
icantly different between patients undergoing CEA and
CAS (70.2 vs 72.0,respectively, P0.36). CAD was more
common in patients undergoing CAS (60.3% vs
39%,P0.003). The prevalence of COPD, ESRD, Hyper-
tension and diabetes were not significantly significant.
Mean hospital cost for CAS was $9426/5776 while
CEA cost was $6734/3935 (P  0.0001). This cost
differential was driven by the higher direct supply costs for
CAS ($5634) vs CEA ($1967),(P  .0001). These
higher costs for CAS were seen consistently in symptom-
atic, asymptomatic, elective and urgent subgroups (Table).
30 day stroke/death/MI rate was 2.3%(4/174)in the CEA
group and 3.8%(5/132) in the CAS group,P0.5. Overall
LOS was 2.1 days in both groups (P0.9).
N
Length of
Stay (days) Cost ($) P
CAS CEA CAS CEA CAS CEA
Entire Cohort 132 174 2.1 2.06 9426 6734 0.0001
Symptomatic 45 78 3.5 2.85 12128 7750 0.0001
Asymptomatic 87 96 1.3 1.43 7983 5835 0.0068
Elective 118 152 1.4 1.34 8538 5841 0.0001
Urgent 14 22 7.5 7.05 16095 12540 0.0542
Conclusions: Treatment of carotid artery disease with
CAS was 40% more costly than CEA and did not provide
better clinical outcomes or a reduction in LOS. The cost
differential was driven entirely by the increased supply costs
in the CAS cohort. At present, carotid stenting cannot be
considered a cost-effective treatment for carotid artery
disease.
Author Disclosures: H. Bazan: Nothing to disclose;
G. D. Crenshaw: Nothing to disclose; T. Smith: Nothing
to disclose; W. Sternbergh: Nothing to disclose.
C3e: Poster Session - Peripheral Arterial
Disease (1)
PS98.
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Objectives: To analyze early and long term results of
endovascular infrainguinal peripheral revascularizations in
female patients in a single centre experience.
Methods: From January 2000 to March 2010, 223
consecutive endovascular interventions for femoro-popli-
teal disease in 214 patients were performed. Interventions
were performed in females in 71 cases (group 1) and in
males in 152 cases (group 2).
Early and follow-up results were analyzed and com-
pared with appropriate statistical tests.
Results: There were no differences between the two
groups in terms of risk factors for atherosclerosis, comor-
bidities, clinical status, TASC II classification of arterial
lesions and technical characteristics of the procedures.
Technical failure rate was 3.9% in group 2, while no
failure occurred in group 1 (p0.09).
Cumulative 30-day mortality was 0.9%, with no differ-
ence between females (no deaths) and males (2 deaths,
1.3%; p0.3). Overall amputation rate at 30 days was 1.3%,
again with no differences between the two groups (2.8%
and 0.7%, respectively; p0.2); also the rate of periopera-
tive thrombosis (overall 2.7%) was similar between the two
groups (2.8% and 2.6%, respectively; p0.4).
Follow-up was available in 95 % of patients with a mean
duration of 17 months (range 1-85).
Estimated 36-month survival rates were 95% in group 1
and 81.8% in group 2 (p0.3; log-rank 0.9). Primary,
assisted primary and secondary patency rates at 36 months
were 39.8%, 49.1% and 62% in group 1 and 41.3%, 55.5%
and 75% in group 2, without significant differences be-
tween the two groups. Also the rates of freedom from any
(open or endovascular) reintervention and from conversion
to surgical bypass at 3 years were similar. In patients with
critical limb ischemia, limb salvage rates at 36 months were
80.5% and 90.3, respectively (p0.7, log-rank 0.2).
Conclusions: Endovascular treatment of femoro-pop-
liteal occlusive disease provides similar results between
males and females at an intermediate follow-up.
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Objectives: Cardiac risk factors encompassed in the
Revised Cardiac Risk (RCR) index help identify patients at
the highest cardiac risk in the surgical population. Recently,
high-sensitivity C-reactive protein (hs-CRP), the common
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carotid artery intima-media thickness (CCA-IMT) and the
ankle-brachial index (ABI) were separately associated with
outcome after vascular surgery. Aim of the study was to
evaluate if these risk markers have an added predictive value
even on top of the RCR index.
Methods: A total of 647 patients with hs-CRP, CCA-
IMT and ABI assessment prior to surgery were included.
The primary endpoint was a composite of cardiac death and
non-fatal myocardial infarction.
Results: Based on multivariate hazard ratios (HRs), a
baseline hs-CRP6.5 mg/l was not predictive of a 30-day
cardiac event, in contrast with a CCA-IMT1.25mm and
an ABI0.91. However, all three risk markers had a signif-
icant association with long-term adverse outcome (Table).
Hazard ratios (HR) and odds ratios (OR) for cardiac
events after vascular surgery
30-day events HR 95% CI p-value
Cumulative
2
Revised cardiac risk
index 1.65 1.39-1.95 0.001 98.9
hs-CRP 6.5mg/l 1.10 0.82-1.49 0.521 99.3
CCA-IMT 1.25 1.44 1.07-1.94 0.016 105.1
ABI 0.90 2.05 1.53-2.74 0.001 125.2
Long-term events OR 95% CI p-value
Cumulative
2
Revised cardiac risk
index 1.69 1.45-1.98 0.001 152.4
hs-CRP 6.5mg/l 1.53 1.17-2.00 0.002 163.8
CCA-IMT 1.25 2.40 1.84-3.12 0.001 176.5
ABI 0.90 2.21 1.69-2.89 0.001 209.6
Multivariate analysis corrected for gender, age, hypertension, hypercholes-
terolemia, smoking and chronic obstructive pulmonary disease.
Conclusions:The current results show that combining
risk markers with risk factors as embedded in cardiac risk
indices can improve perioperative and long-term risk pre-
diction in vascular surgery patients. These additions to risk
prediction models should be investigated in other
populations.
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Objectives: To determine the viability, safety, and ef-
ficacy of various forms of atherectomy devices over a 5 year
period in the treatment of lower extremity arterial occlusive
disease. In addition, to determine if EPD use confers any
benefit with regards to distal embolization during the
atherectomy procedure.
Methods: Retrospective review of 150 limbs in 148
patients treated with atherectomy at a single institution
over a 5 year period. The atherectomy devices included
laser, rotational, and orbital atherectomy. Patient charac-
teristics, type of device used, success of delivery of atherec-
tomy device to target lesion, reconstruction techniques,
rate and type of complications, and subsequent procedures
were all examined. The use of EPD’s in atherectomy pro-
cedures were also examined with regard to the rate of distal
embolization.
Results:Median age of patients was 64.80% were male.
Successful delivery of atherectomy device to target lesion
was 93.3% (n140). The limb level of atherectomy inter-
vention was the superficial femoral artery in 60.7% (n91).
Median length of vessel treated was 12 cm. Majority of
reconstruction following atherectomy was balloon angio-
plasty alone in 63.3% (n95). Reconstruction success was
86.7% Vessel rupture or extravasation was seen in 13.3%.
78% of limbs did not require any further intervention. Rate
of major amputation after atherectomy was 9.3%. 26.7% of
limbs (n40) received an EPD prior to atherectomy, while
73.3% (n110) did not. The rate of distal embolization
was 12.5% in the EPD group and 15.5% in the non-EPD
group (p0.65, NS).
Conclusions: Atherectomy is a safe, viable, and effec-
tive method of intervention for lower extremity arterial
occlusive disease. The majority of patients required angio-
plasty alone as reconstruction after atherectomy. Subse-
quent rates of futher intervention or amputations were low.
In the embolic protection substudy, there was no signifi-
cant difference in the rate of distal embolization between
patients treated with or without an EPD.
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